Vor Biopharma (VOR) Share-based Compensation (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Share-based Compensation data on file, last reported at $8.9 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $8.9 million, up 358.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.8 million (up 197.15% YoY), and the FY2025 annual result was $18.9 million, up 92.06% from the prior year.
• Share-based Compensation improved to $8.9 million in Q1 2026 per VOR's latest filing, from $7.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $8.9 million in Q1 2026 and troughed at $1.7 million in Q4 2024.
• A 5-year average of $3.6 million and a median of $3.1 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2026: Share-based Compensation slumped 51.17% in 2023, then jumped 358.87% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $3.9 million in 2022, then tumbled by 51.17% to $1.9 million in 2023, then retreated by 9.77% to $1.7 million in 2024, then jumped by 315.8% to $7.1 million in 2025, then climbed by 24.82% to $8.9 million in 2026.
• Business Quant data shows VOR's Share-based Compensation at $8.9 million in Q1 2026, $7.1 million in Q4 2025, and $8.0 million in Q3 2025.